Photo by blueriverstudio from unsplash
The recent introduction of four biosimilars to the anti‐TNF monoclonal antibody adalimumab has raised the prospect of significant cost savings for the NHS. But what are biosimilar medicines, how easy… Click to show full abstract
The recent introduction of four biosimilars to the anti‐TNF monoclonal antibody adalimumab has raised the prospect of significant cost savings for the NHS. But what are biosimilar medicines, how easy is it to switch patients and how likely is it that large savings will be possible?
Keywords:
drawbacks moving;
biosimilar medicines;
moving biosimilar;
benefits drawbacks
Journal Title: Prescriber
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!